<SEC-DOCUMENT>0000950170-24-041619.txt : 20240404
<SEC-HEADER>0000950170-24-041619.hdr.sgml : 20240404
<ACCEPTANCE-DATETIME>20240404083055
ACCESSION NUMBER:		0000950170-24-041619
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240404
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240404
DATE AS OF CHANGE:		20240404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		24821722

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cadl-20240404.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-03T17:26:11.7830+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:cadl="http://www.candeltx.com/20240404" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d2d9a04a-1b51-49ec-8088-ef39bcd85abc" name="dei:EntityCentralIndexKey" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad">0001841387</ix:nonNumeric><ix:nonNumeric id="F_7b44c99f-3264-42a4-8fb8-744420d66789" name="dei:AmendmentFlag" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cadl-20240404.xsd"/></ix:references><ix:resources><xbrli:context id="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001841387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-04</xbrli:startDate><xbrli:endDate>2024-04-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1cda446-5962-4c00-96b2-6d561b702aef" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_348ec758-f7a4-43c3-8e27-67942c44071a" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 4, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7ea0311-fbfe-4fcb-981b-7ffb2d3d6c93" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">CANDEL THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3506ed55-1493-4cb5-b78c-9b5185c41394" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e48287ee-c386-43d1-9a8d-95ebab1297a2" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40629</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_492e5961-7966-49cb-a21f-696bf4708638" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">52-2214851</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_555cc1a5-4b53-4ad4-bef0-618c53d9591d" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">117 Kendrick St</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">., </span><span><ix:nonNumeric id="F_820d5813-e5cc-4607-99a9-5d1663c7fb8d" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 450</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_0b6c66cc-1e3b-4297-831b-1a693f8b6964" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Needham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_367a0284-0ada-4527-80a6-be98e0e13b33" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3e0544e4-35d3-40b1-be9d-6b895d977ddc" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02494</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a99461f-3cc4-48d8-841d-ea6ed9b5fb40" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f67ae47-edc8-44ba-bb67-61e8215dcef2" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">916-5445</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4fb14b76-2cdf-41c9-bd1b-6af072d58c40" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_18d2271c-19ec-479c-a4fd-dd8a0bb67633" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_95bf41ef-9211-4b40-ae96-71a991791062" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_122a5997-f58d-48b7-9708-ba4951fc04be" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_93b15b7d-d483-444f-b217-0f08dcd532f6" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8c978fbf-1824-4101-b719-92dda706ddc2" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CADL</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f8228aa6-f7d1-4e60-98dd-a7ea8d8468f8" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fef36247-80f6-47fb-9322-3044641432ef" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_031b3e04-67df-448f-8c84-5d7142be9a4a" contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2024, Candel Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing positive interim data from its randomized phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 4, 2024, the Company announced positive interim data from its randomized phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer (as of a March 29, 2024 data cut-off):</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) (n=13)</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimated median overall survival was 28.8 months in the CAN-2409 group versus only 12.5 months in the control group.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients, after standard of care (&#8220;SoC&#8221;) chemoradiation and prior to surgery, versus only 16.7% in the control group. At 36 months, a survival rate of 47.6% was estimated in patients who received CAN-2409, together with SoC chemoradiation prior to surgery, versus only 16.7% in the control group.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Previous analysis of blood and resected tumors showed consistent and robust activation of the immune response after experimental treatment with CAN-2409 </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In pancreatic tissue of patients treated with CAN-2409 plus prodrug together with SoC (but not SoC alone), dense aggregates of CD8+ granzyme B positive cytotoxic tumor infiltrating lymphocytes, dendritic cells, and B cells were observed in the tumor microenvironment.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increased levels of soluble granzymes B and H, as well as pro-inflammatory cytokines, including IFN-&#947;, were observed in peripheral blood after CAN-2409 administration, but not after SoC.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAN-2409 continued to be associated with a favorable safety/tolerability profile</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Addition of CAN-2409 regimen to SoC was generally well tolerated, with no dose-limiting toxicities, including no cases of pancreatitis.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"/>
    <td style="width:2.02%;"/>
    <td style="width:90.9%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cadl-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated April 4, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"/>
    <td style="width:5.04%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Candel Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: April 4, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Peter Tak</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paul Peter Tak, M.D., Ph.D., FMedSci</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cadl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img160460863_0.jpg" alt="img160460863_0.jpg" style="width:222px;height:98px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer</font></p>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in borderline resectable pancreatic ductal adenorcarcinoma (PDAC) </font></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation. At 36 months, estimated survival was 47.6%</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">in the CAN-2409 group versus 16.7% in the control group </font></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">No new safety signals were observed, providing further support that multiple injections of CAN-2409 were generally well tolerated, with no dose-limiting toxicities and no cases of pancreatitis</font></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Previous analysis of resected tumors showed dense aggregates of immune cells, including CD8+, cytotoxic tumor infiltrating lymphocytes, and dendritic cells, in PDAC tissue after CAN-2409 administration, confirming activation of a robust antitumoral immune response</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">NEEDHAM, Mass., April 4, 2024 (GLOBE NEWSWIRE) &#x2013; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Administration (FDA) granted Fast Track Designation to the Company for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,&#x201d; said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. &#x201c;We are very  encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Data Highlights as of a March 29, 2024 Data Cut-off, Include:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC (n=13)</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Estimated median overall survival was 28.8 months in the CAN-2409 group versus only 12.5 months in the control group. </font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">At 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients, after SoC chemoradiation and prior to surgery, versus only 16.7% in the control group. At 36 months, a survival rate of 47.6% was estimated in patients who received CAN-2409, together with SoC chemoradiation prior to surgery, versus only 16.7% in the control group. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Previous analysis of blood and resected tumors showed consistent and robust activation of the immune response after experimental treatment with CAN-2409</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">In pancreatic tissue of patients treated with CAN-2409 plus prodrug  together with SoC (but not SoC alone), dense aggregates of CD8+ granzyme B positive cytotoxic tumor infiltrating lymphocytes, dendritic cells, and B cells were observed in the tumor microenvironment.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Increased levels of soluble granzymes B and H, as well as pro-inflammatory cytokines, including IFN-&#x3b3;, were observed in peripheral blood after CAN-2409 administration, but not after SoC. </font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-2409 continued to be associated with a favorable safety/tolerability profile</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Addition of CAN-2409 regimen to SoC was generally well tolerated, with no dose-limiting toxicities, including no cases of pancreatitis</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells,&#x201d; said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. &#x201c;The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patient&#x2019;s anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About Candel Therapeutics</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel,  genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable PDAC (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel&#x2019;s enLIGHTEN&#153; Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">For more information about Candel, visit</font><font style="color:#002060;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">: www.candeltx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About the Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This randomized, open-label phase 2 clinical trial is designed to evaluate the safety, preliminary efficacy, and biologic activity of a 2-3 injection regimen of CAN-2409 plus prodrug (valacyclovir or acyclovir) in patients with borderline resectable PDAC who are being treated with neoadjuvant chemoradiation prior to resection. After a protocol amendment in 2022, when enrollment of patients with locally advanced PDAC was discontinued, the clinical trial was designed to exclusively focused on borderline resectable disease. The clinical trial remains active but is not currently unrolling new patients. In a previously completed phase 1b clinical trial, a highly significant increase in the number of CD8+ tumor infiltration lymphocytes was demonstrated at the site of the tumor after CAN-2409 treatment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About CAN-2409</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-2409, Candel&#x2019;s most advanced multimodal biological immunotherapy candidate, is an investigational off-the-shelf replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient&#x2019;s specific tumor and induce an individualized, systemic immune response against the disease. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together this regimen is designed to induce an individualized and specific CD8+ T cell mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ vaccination against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. Furthermore, to date, more than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with other therapeutic strategies without inordinate concern of overlapping adverse events.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Currently, Candel is evaluating the effects of treatment with CAN-2409 in NSCLC, borderline resectable PDAC, and localized, non-metastatic prostate cancer in ongoing clinical trials. CAN-2409, plus prodrug (valacyclovir), has been granted Fast Track Designation by the FDA for treatment of PDAC or stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy. The Company&#x2019;s pivotal phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About Pancreatic Ductal Adenocarcinoma (PDAC)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Pancreatic cancer is a highly lethal malignancy, and is the fourth leading cause of cancer-related death in the United States among both men and women. Based on the National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) database, pancreatic cancer is expected to account for 3.3% of all new cancer cases with an estimated 64,050 new cases and estimated 50,550 deaths in 2023.  Effective therapeutics for pancreatic cancer, including PDAC, which accounts for 90% of all pancreatic carcinomas, are urgently needed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Surgical resection offers the only chance of cure, thus a major therapeutic goal for subjects with non-metastatic disease is to achieve complete tumor resection. Surgical treatment (pancreaticoduodenectomy, also known as the Whipple procedure) or total or distal pancreatectomy (depending on tumor location) is generally the recommended treatment for patients diagnosed with resectable cancer; the addition of adjuvant chemotherapy has been shown to only slightly improve survival rates (20 to 23 months).</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Arial;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">  To this end, there has been increasing use of neoadjuvant chemotherapy and chemoradiation regimens for subjects with borderline resectable pancreatic ductal adenocarcinoma. Neoadjuvant regimens are intended to debulk the tumor, thereby increasing the proportion of patients who may become eligible for surgical resection and achieve complete resection (i.e., resection with negative margins, designated &#x2018;R0</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">resection&#x2019;). Unfortunately, even when an R0 resection is initially achieved, cures remain elusive as most patients experience disease recurrence due to residual micrometastatic disease. In a recent meta-analysis of 20 studies representing 283 patients with borderline resectable PDAC, neoadjuvant FOLFIRINOX with or without radiotherapy, median overall survival was only 22.2 months (95% CI, 18.8 to 25.6 months).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Immunotherapy with PD-1 antibodies with or without CTLA-4 antibodies has been uniformly unsuccessful in patients with PDAC due to the dense stroma that surrounds PDAC tissue and the absence of tumor infiltrating lymphocytes.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements,&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, and expectations regarding the therapeutic benefit of the Company&#x2019;s programs, including the potential for its programs to extend patient survival. The words &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;target&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company&#x2019;s ability to continue as a going concern; expectations regarding the therapeutics benefit of the Company&#x2019;s programs; that final data from the Company&#x2019;s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company&#x2019;s ability to efficiently discover and develop product candidates; the Company&#x2019;s ability to obtain and maintain regulatory approval of product candidates; the Company&#x2019;s ability to maintain its intellectual property; the implementation of the Company&#x2019;s business model, including strategic plans for the Company&#x2019;s business and product candidates, and other risks identified in the Company&#x2019;s filings, with the U.S. Securities and Exchange Commission (SEC) including the Company&#x2019;s most recent Annual Report on Form 10-K filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company&#x2019;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">date.<br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Investor Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Theodore Jenkins</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">VP Investor Relations and Business Development</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc.<br>Tjenkins@candeltx.com</font><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Media Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Aljanae Reynolds</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Wheelhouse Life Science Advisors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">areynolds@wheelhouselsa.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img160460863_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_0.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   ?V@
M P $     0   .(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "#_V@ , P$
M A$#$0 _ /[\**** "BBB@ HHHH **** "BBB@"*8R"%FA W[3M!Z9[5\O\
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MPVDJE-Z57T;]/-RL[V8M%%%?M1^(A1110 4444 %%%% !1110 4444 %%%%
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M7]GOX00LFG:5&9+FZF),UY>2X,]S)VW2-S@< <"O"XMEETU"KA6N:6Z6UO\
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M.-O7?DJ_VNC_ (D<^+_A3]&?Y<26\+,$5%))P/E'4_A6O_PBNM9_Y!MWZ?\
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MQL20:)#@W3<'(\YBL0/<;J_I5U"_M-+L)]3OY$B@MHGGFED(5$2-2S,Q/
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MY_\ ^4IU_P#]B%X=_P#1<M?Z5@ZCZU_FI_\ !S]_RE.O_P#L0_#O_HN6ON.
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M#%?1\ _[E7]?T/,S_P#CTOZZG^T/X(_Y$G1_^P9:_P#HE*Z>N8\$?\B3H_\
MV#+7_P!$I73U^5UOCEZGUT?AB%?BA_P<.?\ *(WXK?\ 7#2__3C;U^U]?BA_
MP<.?\HC?BM_UPTO_ -.-O7;DO^]TO5&&*_AR]#_,W^!W_);/!W_8U:5_Z5QU
M_LZI]Q?]T?RK_&*^!W_);/!W_8U:5_Z5QU_LZI]Q?]T?RK[KQ'_BT/1G@<-?
M!4]1U!Z445^9'TQ\\?M3_LU_#+]KCX%>(?@+\6;%+W1]>L)+9U(^>"4KF*>)
MN=LD;X92!P17^1Y^U3\ O$/[+?[17C']GSQ26>Z\*ZY<:8)B,>? IW03=O\
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MC;&_P:ENS_(_S4/@3_R73P3_ -CCH?\ Z70U_LN>'O\ D V7_7I%_P"@"O\
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M_:;N[==JRF/.X0Q,0SOC ''4U_E9>,/%?BKXI>.M2\:>)9IM0UO7]4FU"\E
M+R7%W>2EVP.I+.V !]*_3/#_ "R:G/%S6B5D?,\1XI<JHK=G]9__  :._"Z\
MU/X\?$SXNR1M]ETSP]:Z1%+C@SW,I=ESZA!FO[RCR!]<U^(G_! _]A>__8F_
M89TJ/QA;&V\4^,Y1XGUV&1=LD'G*/L\#9YRD>,CU-?MV*^3XHQD<1C:DX[+3
M[CU\KH.G0C%BU^'7_!Q5_P HH_B'_P!=-+_]+X*_<6OPZ_X.*O\ E%'\0_\
M?TO_ -+X*X\C_P!]H?XH_FC7&_P:GH_R/\S+X:>'K#Q=\2_#GA+5-XM=5U_3
M=,N3&</Y-W<QPN5/8[6.#ZU_H,Z7_P &KO\ P3LOM-M[V74?'(:6".5@-2&
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MC36_VR/BY8?MFP?L]VGA5GT)[F*UDOS#-YS)+&':[60?N_*0G!&.QYS7T_\
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M<>:>.F.F?^!5^7?[7_\ P=C?#W3=)N?#_P"Q9X/OM2U"2,QQ^(/%ZK;VT)/
M=+2)F>0CJ-S@>HK^.R/]D#]K*2[_ +/B^&7C\S$[?+&@W^<_]^?ZU]J_ +_@
MB+_P4N_:$U2"TT#X::KH-I,RA]3\6%=+MXE;^(K)F8_\!C/X5ST^%<JH/VE2
MI=+NU8VGFV+J+EA"S]#Y2^)?[<_[5GQ8^/L?[3?C3QIK4WC&VOEO[#4HYVB%
MFR-N2.WC4A$C7H$ P1UK_3K_ ."2W[2?QY_:O_8A\*?&+]HWP_)H/B.]C>%S
M(AB_M&"'"Q7PB;YD$X^;;^(P#7Y"_P#!-_\ X-E_@C^SGJ]C\5OVNKRU\?\
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M359RHJ-1:K0D'4?6O\U/_@Y__P"4IU__ -B'X=_]%RU_I5].:_@R_P"#B/\
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MYDU<]S+L14JP<JD;,DHHI",U\Z=Q_$G_ ,'@)(N/@>1_?\28_P"^+&OY[O\
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M.TOPK*_PSL-'M1=>*3=VJQ*\6@7%FR" R^>7$[JG$>.<]*_6O_@JQ^PWI/\
MP4$_8H\5_ ,1P#7?)&M^#[V?Y?LNMV*E[9MQZ)+\T$F?X)&Z8%?8T\]ITI86
M$DG'E2>FJ?\ P#RJF"E)57%M.Y!_P2U_8/\ V??V"OV7M+\"? &\;7;?7TA\
M1ZEXNFV>=KDMS"IBNOD^58?*($,:DA4/4DL3^D9]/:OPO_X(&^%?VYOA)^R-
M-^SM^VUX3O/#TW@F_6S\'WUY>6UV]YI%R&E$!^SRRX^R2;E4MC,;HH^X<_L/
M\8]>\:^%?A3XD\2_#72GUSQ!8:+>WFB:-'(D37M]#"S00"24JB^;( I9B  <
MU\GF5.3Q4XRGS7>YZ>&DE334;>1_$#_P<3_MH?#3]H+]OCP!^PYXW\2+HGPS
M\ ZO9W_Q#U:W22Y$=_?%6G'DP!G>2UL2550"1),P."#C=_X+7?\ !0/_ ()-
M_MK?L0:-\./V>?&AC\9?#:[LKWP%9_V-?VRM;0JMK/8K-)"J1JUOAE+$#=$N
M2*^^?^",7_!'_P 6&Y^)G[4W_!4/P-I&L^/O'?B2:2WT7Q1#9ZNMM \ANKB[
M #3Q(]Q/)L4 Y6.( 8#$5^Z<W_!-?]@22%XQ\&_AL-RD9'AZPR,C_KB/Z5]7
M/-<%AI4:<4W[/JGI?J>2L%6J*<FTN8^9/^"(G[;W_#<G[!7A?QAKES'-XI\,
M0KX1\5KNS*;RP15BN''7_28/+DR1\S;_ $K]>&^Z?I7\KG_!,K]A+]L#_@FU
M_P %3?B3X!\&^&+N[_9[\=--=V6N1WEKY%BR*;NQ_<-*)]T#/)9MA.48-SBO
MZI".,>U?,YW2I1Q$I47[LM5\^AZ>#E+D2GNM/^"?YX?[:NB_M;^(/^#@[Q/I
M?[#]_;:;\1Y-/M?[&O+QX8XUB70D-R-UPDD?S0;QROY'FOM;7?\ @EE_P7I_
M;[DL_@]^W/\ $_2=)^'R7L5[JT=M<PS//L/&VUL8(5F<?P^=($4X/)%?7GAK
M]@']K:/_ (.';O\ :_N/"<D?PX&DN%\3/=VOELYT3['L6$2F?=YYVXV8Q\V<
M<U_57QGIWKW\QS]THT8T5%M16O5'GX?+^>4W4;5V_F?/_P"R]^SC\.OV2?@3
MX<_9[^%%NT&A^&M/2QMC*099GSNEFE(QF25R78XQD^F*9^UE_P FP_$#_L3]
M5_\ 29Z^@Z\9_:*\,:UXT^ OC+PCX;A^TZAJ?AK4;&RM]RKYDTT#HB[F(498
M@9)Q7RE&JW7C.;ZIO[SU90]QQ2Z'^?%_P15_X(X+_P %'O@1XC^)!^*?BCP)
M_8FO1Z3_ &=H42O%/O@$@E8F1/FYQTZ5_5)_P3:_X(GG_@GK\<;OXS)\7O&'
MC1+K1I](;1M718K7]\ZL)3MD;++MX&*_GK_X)]?#K_@X7_X)K_#;5OA?\ ?@
MEH%S8:SJ:ZM>MXC>SNYA.D0BQ&T.JVZA,#H5)SWK]@?V3_VL?^#B#QE^T7X2
M\,?M*?!WP1HO@2]U5(?$^JV,423VUD58L\975YSN! _Y9-]*^YSR>(JSJN%>
M/(^EU?3Y?J>+ET:<%%>S=^^MC^G$GTK^.#_@Z_MY;6_^ OB&X&RSA\3W"2SG
M[J$-&YR>GW1FO['SR>/_ -?^?K7YO_\ !4/_ ()U^ _^"D_[--Y\%_$ER-+U
MFTE_M/POKFW?]AOT&%+J/O1./ED'7'(Y%?(Y#CH8?%4ZD]EI]Z/4Q])U*,DO
MZL?;7PAU"RU7X5>&=2TZ5)X)_#^GR131X*LK6Z$$$<$5_(3_ ,%L)HM4_P""
MV7[,6AZ<RSWD&JZ9//;1$.Z(=11P649(^52W/89KSSX3ZE_P<R_\$^O"9_9B
M\ > ],^(>@:9NT[P_KLL-KJR6UN,A##<?;+641@<JEU&P7IC%?:/_!+3_@DM
M^V%KO[7A_P""E_\ P5!U5+SQU$)7\/>&O-ANFM9)(FA66?R?]'A6%&(A@B)"
MDY)[5[]' T\'*KB9UDTTU%+=MKMT.">(E64:48.Z:O?96/ZJ+8@V\9'_ #S'
MY<5,WW3]*7IQQ^'2FMRI KXSFU/;CV/XT?\ @FQS_P '+W[0?_8*\1?^EMG7
M]F%?S#?L,_L*_M2_"O\ X+M?&G]JGQYX5EL/ /B+3=8BT/Q UU;21W3WEU;2
M0JL*2M,N5C8G<@QCW%?T\U[G$%>,ZT'%_9B<&7P<82NNK/-?C+_R2/Q0/^I=
MU+_TEDK^3#_@T8_Y$3XZ?]C;I1_\E7K^N/XE:-J'B+X>:[H&DJKW5]H][9VR
MLP53+- Z("3T&XC)K^<__@V__89_:C_8K\'_ !:L_P!ICPP_AF;Q!XGLKC2(
MI;JVN6N(;>!E>0?9Y)-J[F &[!/I5X&M!8#$TV]7R_F&(C+V])V[G],4RL\+
MHHR2I 'N17\,'P*\5Z=^QQ_P=%^-K?XV&'3K?Q[?:Q8:+J%VWEPJWB18;W3F
M\QAC$I06X/3>VW/6O[HSTK\0O^"Q'_!&SP-_P4S\)6/C'PAJ$/A7XH^&HF30
M/$CH3!=P9WK97WECS/+#_-'*N7B8D@$$K49#CJ=*=2G5=HU(N-^U^H\PHR<8
MRAO%W]3]N@ ,8I^#7\2G@+XH?\'2G['FC_\ "DX_ UK\2[*QC&EZ5KVI16>M
MND2C$96^BN[69U (^:[5B,8/3%?9/_!-K]C?_@M)\2_VP-*_;;_X*#_$74?#
M&E:3;W-M#\/K*\AD34()D9!:RV%FWV&VMU<B0M\\S.JX*\M6M?((TX2J2KQM
MTL[W\K$4LP<FHJF[]3^J$D5\+?MV?\$[?V8_^"B?PU3X<_M%:*UTUBS3:+KE
MA)]FU/3)G7!>VG ; 88W1N'C?C<IQ7W1@DY/X\_XU_.#_P %6/V<O^"QFD?M
M.:9^V7_P3L\;_P!J:7IFB0:+/\+YIXX(-N\O<.UK=D6EZL[D$EV2:,X$9P!C
MS<IIR=9*-50:V;_(ZL2UR:QYO(_&7]I_]B?_ (*)_P#!OBL/[4/[(7Q,O?%7
MPLBU2WMM:TC4T(BMOM#A(4U*PW&"6*5V$:W,/ER*Q'"Y!K^Q[]@W]JS1OVX?
MV1? W[4FAVG]FIXLTC[5=:=N,@M;ZWE>UO( _&Y8[B&15)&2H&>:_E!_:4TO
M_@X?_P""L/@JT_9&^+?PH\/_  P\)7VI6\GB;6)=EE:W1M'$L;3N]Y=SO#'(
MHD$=O'EV5<MBOZS?V'OV6/#/[$?[*7@K]ESPE=3:A:>$M)^R2:C(H1[R\GE>
MYO+@KR%\ZXED<+_"#C)QFOH,_FOJ\/;R3JWZ6V\_,\_ 1:J2=.ZC;KW\C__3
M_OPHHHH **** "BBB@!.U?D/^W+XKT[]I+Q=;_LF?"OQ&=/\5VE\MS=V-SYL
M%E=A83)Y#7,:G]XBD2!2,'&,YQC])OC)\2- ^%?P_O\ Q9K^I66E+'%Y5M=W
MY_<K<2_)#N"@L07(X':OEC]E#X!^)8KJ3XY?M"Z=X>NO'MS<2?9==TI02UB\
M:K&Q*!(RS#.&"[O+(!/6OS/CVG6S&5/),/HJFM1ZZ0[)IWC)].FC/T[P_KT<
MKC4SRO\ %3TI+36?1M-6E&/VNNJ/HC]G3X:^)/A/\(-#\#>,=0_M75-/LD@N
MK[+-N8$D(K.=Q5 0BDXX'/I7N/>EHK[_ "W+Z>$H4\-1^&"27HE;5]7YGY]F
M./J8JO4Q-7XIMM]%=N[TZ(3W%>?_ !.^(/AWX6>!-3\>^+&=-.TVT>YN3&-S
M%5!^51W)Z &O0,CK7S/^UWXQ^'G@?]G[7]9^*%A<:IHSVPM+FPM2!+,;@A%5
M6R-N2P^;/%<V?X[ZM@:^(C)1<(MW>RLNOEW.SA[ ?6<=A\.X.7/**M'=W:T7
MGV/S(_8RU#]D#XV_M-WOC#PSX;UO2/$2//K&GVVH72SV+.6S),D:<QR9;=M)
M90<D<U^YX  P*_*'_@FC\+/V?)O#UY\:?A;9:[#?RSRZ5*-?F29[<#:Y2%HE
M52K K\Q&[M]?U>]Z_.?!3 UJ620KXB,.>JW)NFK)I]?4_2/'#'8>KGM3#X9U
M.2BE!*J[RBUNO0^3?VDOC#^S/\*Y]*F^.QTY[IYO-TV*XMOM<Z%3S*JA6957
MNW'UKZ0\*^)/#_B[PY9^)?"MQ#=:=>P+/:3P',;QL.",?Y'2O@3]M7]A"7]J
M7Q%I?B[1M;_LJ]LH393I-#YT3P%MV5 *D.#]0?:OLGX+?"S2_@M\,=(^&>BR
MRSP:5:K;B>;&^1NK,1VR2>!P/>O9R2OG#SO&T\3A80P]ER37Q2?GU_R/%S[#
M9*LAP-3"XN<\3=\\'\,5Y?AZF_\ $*;[+X)U2\^P+J9AL9I5L9$#B8HI(0@@
MY!Q7X8_L8?ME?'SQC^T=:_#B\@LCH-[<312Z-96,=O'IL:$_,IB4,-N,'S,Y
M]J_H"(^4CK]:_)+]H'_AJ/P5^U;H%U\(]-M--\*7MY9KJ-_;6MK'!/OE N!>
M3NH?.W.T;AGMDU\MXKX3$T,3E^;T:TH1I32E&*OS)M;OLON/J/"7%86OALPR
MBOAX3G5@W"4Y647%/9=WTMJ?K?14<;!T5LC) Y7H3[>W6I*_:XRNKGXBT%+D
MCI244Q!1]:** #_.31110 N?\FD-%% !R.1G']:-Q]_\_C110 IR3S_G]:2B
MB@!2?\]Z2BB@ '(Q^E%%% !G/6BBB@ [^OO1110 N3_]>DHHH **** '%FQ[
M?K_.F[C[_P"?QHHH *.M%%  >OX]Z4=.WX4E% !1110 I)]3CTI*** "CG\*
M** "BBB@ ]SV]:,8XZ\_YQ110 4HZTE% !TZ#&>N,=?UHHHH __4_OPHHHH
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cadl-20240404.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-03T17:26:12.0785+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.candeltx.com/20240404" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cadl="http://www.candeltx.com/20240404" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cadl-20240404.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140077636648560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CANDEL THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001841387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2214851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick St<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">916-5445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CADL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'I0-([/BC7TM#;S_%X<[SF!QVAO@^D9*\]:P'P&J;SCC?P%02P,$%     @
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MVD.$6 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #:0X18XQ@BN>X    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #:0X18F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( -I#A%C('(P!B 0  ,\1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #:0X18GZ ;\+$"
M  #B#   #0              @ '+#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( -I#A%B7BKL<P    !,"   +              "  :</  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( -I#A%@<.&7J/P$  #P"   /              "
M 9 0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #:0X18)!Z;HJT   #X
M 0  &@              @ '\$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #:0X1899!YDAD!  #/ P  $P              @ 'A
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cadl-20240404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cadl-20240404.htm">cadl-20240404.htm</File>
    <File>cadl-20240404.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cadl-20240404.htm": {
   "nsprefix": "cadl",
   "nsuri": "http://www.candeltx.com/20240404",
   "dts": {
    "inline": {
     "local": [
      "cadl-20240404.htm"
     ]
    },
    "schema": {
     "local": [
      "cadl-20240404.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240404.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240404.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.candeltx.com/20240404/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-041619-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-041619-xbrl.zip
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M@P%O'YQ0B!D\#&;P'EF\J12/B@7+"[,)U$7" 0GPEMBLL>3"_<OLDGB3S',
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MLZ=#2>ZC!L%'&T-9]0<<"2,?VAO":CY/$<2T,8;5?VXC6"D[GDVR7//9I**
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M-"YH=&U02P$"% ,4    " #;0X18,K-;*T\)  #F;   $0
M@ '6%P  8V%D;"TR,#(T,#0P-"YX<V102P$"% ,4    " #;0X184AE0HJ\9
M  !FH0  #P              @ %4(0  8V%D;"UE>#DY7S$N:'1M4$L%!@
0   #  , NP   # [      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cadl-20240404_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cadl-20240404.xsd" xlink:type="simple"/>
    <context id="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001841387</identifier>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_d2d9a04a-1b51-49ec-8088-ef39bcd85abc">0001841387</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_7b44c99f-3264-42a4-8fb8-744420d66789">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_d1cda446-5962-4c00-96b2-6d561b702aef">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_348ec758-f7a4-43c3-8e27-67942c44071a">2024-04-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_b7ea0311-fbfe-4fcb-981b-7ffb2d3d6c93">CANDEL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_3506ed55-1493-4cb5-b78c-9b5185c41394">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_e48287ee-c386-43d1-9a8d-95ebab1297a2">001-40629</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_492e5961-7966-49cb-a21f-696bf4708638">52-2214851</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_555cc1a5-4b53-4ad4-bef0-618c53d9591d">117 Kendrick St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_820d5813-e5cc-4607-99a9-5d1663c7fb8d">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_0b6c66cc-1e3b-4297-831b-1a693f8b6964">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_367a0284-0ada-4527-80a6-be98e0e13b33">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_3e0544e4-35d3-40b1-be9d-6b895d977ddc">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_0a99461f-3cc4-48d8-841d-ea6ed9b5fb40">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_2f67ae47-edc8-44ba-bb67-61e8215dcef2">916-5445</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_4fb14b76-2cdf-41c9-bd1b-6af072d58c40">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_18d2271c-19ec-479c-a4fd-dd8a0bb67633">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_95bf41ef-9211-4b40-ae96-71a991791062">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_122a5997-f58d-48b7-9708-ba4951fc04be">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_93b15b7d-d483-444f-b217-0f08dcd532f6">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_8c978fbf-1824-4101-b719-92dda706ddc2">CADL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_f8228aa6-f7d1-4e60-98dd-a7ea8d8468f8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_fef36247-80f6-47fb-9322-3044641432ef">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_8b5673e5-7ba2-4c6a-85b9-e3e169b135ad"
      id="F_031b3e04-67df-448f-8c84-5d7142be9a4a">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
